PRME241220C5000
- 0.04
- 0.000.00%
Prime Medicine Newsroom
Wilson Disease Pipeline Market Research Report 2024: Comprehensive Insights on 5+ Drugs Featuring Vivet Therapeutics, Depymed, Prime Medicine, and Deep Genomics
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Maintains Target Price $5
Prime Medicine, Inc. (PRME) Gets a Hold From Morgan Stanley
A Quick Look at Today's Ratings for Prime Medicine(PRME.US), With a Forecast Between $7 to $14
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Prime Medicine Reports Q3 2024 Financial Progress
Prime Medicine Is Maintained at Buy by Chardan Capital
Prime Medicine, Inc.: Strategic Initiatives and Promising Developments Drive Buy Rating
Stifel Nicolaus Sticks to Its Hold Rating for Prime Medicine, Inc. (PRME)
Prime Medicine Analyst Ratings
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Express News | Prime Medicine Inc : Chardan Capital Markets Cuts Target Price to $15 From $17
TD Cowen Maintains Prime Medicine(PRME.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Nuvalent (NUVL)
Prime Medicine, Inc. (PRME) Receives a Buy From TD Cowen
Prime Medicine | 8-K: Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates
Prime Medicine Reports Q3 EPS (44c), Consensus (44c)
Prime Medicine | 10-Q: Q3 2024 Earnings Report
Prime Medicine: Pro-forma Cash, Cash Equivalents and Investments as of Sept 30 Expected to Fund Planned Ops Into 1H 2026 >PRME
Prime Medicine Initiated IND-enabling Activities for Wilson's Disease Program in 4Q and Remains on Track to File IND And/or CTA in 1H 2026 >PRME